DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Chu, Qian ^a   Han, Na ^a   Yuan, Xun ^a   Nie, Xin ^a   Wu, Hua ^a   Chen, Yu ^a   Guo, Mingzhou ^b   Yu, Shiying ^a   Wu, Kongming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cell cycle; Cyclin D1; Dach1; Proliferation; Renal carcinoma; Tumor growth

Indexed keywords

CYCLIN D1; CYCLINE; DACHSHUND PROTEIN; DECITABINE; TRANSCRIPTION FACTOR AP 1; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; DACH1 PROTEIN, HUMAN; EYE PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CARCINOMA CELL; CELL CLONE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MOUSE; NONHUMAN; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RENAL CANCER CELL LINE; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL GROWTH; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL GROWTH PROCESSES; CELL PROLIFERATION; CYCLIN D1; EYE PROTEINS; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; PROLIFERATING CELL NUCLEAR ANTIGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84964696925     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0073-5     Document Type: Article

References (53)

1. De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD: Dryer D Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control 2014, [Epub ahead of print].
2. Santoni M, De Tursi M, Felici A, Lo Re G, Ricotta R, Ruggeri EM, Sabbatini R, Santini D, Vaccaro V, Milella M: Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. Expert Rev Anticancer Ther 2013, 13(6):697-709.
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ: Global ARCC Trial. temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356(22):2271-2281.
4. Motzer RJ, Molina AM: Targeting renal cell carcinoma. J Clin Oncol 2009, 27(20):3274-3276.
5. Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, Cascinu S, Naso G, Cortesi E: Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. a meta-Analysis of published trials. Cancer Treat Rev 2014, 40(2):271-275.
6. Finley DS, Pantuck AJ, Belldegrun AS: Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl 2):4-13.
7. Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ: Molecular aspects of renal cell carcinoma: A review. Am J Cancer Res 2011, 1(2):240-254.
8. Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A: Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014, 20(16):4349-4360.
9. Dalgin GS, Drever M, Williams T, King T, DeLisi C, Liou LS: Identification of novel epigenetic markers for clear cellrenal cell carcinoma. J Urol 2008, 180(3):1126-1130.
10. Atkins M, Jiang Y, Sansores-Garcia L, Jusiak B, Halder G, Mardon G: Dynamic rewiring of the Drosophila retinal determination network switches its function from selector to differentiation. Plos Genet 2013, 9(8):e1003731.
11. Li X, Oghi KA, Zhang J, Krones A, Bush KT, Glass CK, Nigam SK, Aggarwal AK, Maas R, Rose DW, Rosenfeld MG: Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 2003, 426(6964):247-254.
12. Popov VM, Wu K, Zhou J, Powell MJ, Mardon G, Wang C, Pestell RG: The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab 2010, 21(1):41-49.
13. Wu W, Ren Z, Li P, Yu D, Chen J, Huang R, Liu H: Six1: A critical transcription factor in tumorigenesis. Int J Cancer 2014, doi:10.1002/ijc.28755. [Epub ahead of print].
14. Tadjuidje E, Hegde RS: The Eyes Absent proteins in development and disease. Cell Mol Life Sci 2013, 70(11):1897-1913.
15. Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, Di Vizio D, Wang C, Lisanti MP, Sauter G, Russell RG, Cvekl A, Pestell RG: DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 2006, 26(19):7116-7129.
16. Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, Tian L, Jin M, Pestell RG: The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 2009, 69(8):3347-3355.
17. Wu K, Katiyar S, Li A, Liu M, Ju X, Popov VM, Jiao X, Lisanti MP, Casola A, Pestell RG: Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci U S A 2008, 105(19):6924-6929.
18. Zhou J, Wang C, Wang Z, Dampier W, Wu K, Casimiro MC, Chepelev I, Popov VM, Quong A, Tozeren A, Zhao K, Lisanti MP, Pestell RG: Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci U S A 2010, 107(15):6864-6869.
19. Watanabe A, Ogiwara H, Ehata S, Mukasa A, Ishikawa S, Maeda D, Ueki K, Ino Y, Todo T, Yamada Y, Fukayama M, Saito N, Miyazono K, Aburatani H: Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells. Proc Natl Acad Sci U S A 2011, 108(30):12384-12389.
20. Zhu H, Wu K, Yan W, Hu L, Yuan J, Dong Y, Li Y, Jing K, Yang Y, Guo M: Epigenetic silencing of DACH1 induces loss of transforming growth factor-β1 antiproliferative response in human hepatocellular carcinoma. Hepatology 2013, 58(6):2012-2022.
21. Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, Ertel A, Li Z, Rui H, Quong A, Lisanti MP, Tozeren A, Tanes C, Addya S, Gormley M, Wang C, McMahon SB, Pestell RG: Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res 2013, 73(11):3262-3274.
22. Yan W, Wu K, Herman JG, Brock MV, Zhou Y, Lu Y, Zhang Z, Yang Y, Guo M: Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling. J Cell Mol Med 2014, doi:10.1111/jcmm.12325. [Epub ahead of print].
23. Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, Wang J, Li Z, Addya S, Sorensen PH, Lisanti MP, Quong A, Ertel A, Pestell RG: Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res 2014, 74(3):829-839.
24. Wu K, Li Z, Cai S, Tian L, Chen K, Wang J, Hu J, Sun Y, Li X, Ertel A, Pestell RG: EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1. Cancer Res 2013, 73(14):4488-4499.
25. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL: The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 2009, 119(9):2678-2690.
26. Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL: Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res 2012, 14(4):R100.
27. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL: Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest 2009, 119(9):2663-2677.
28. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL: Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 2012, 31(5):552-562.
29. Powe DG, Dhondalay GK, Lemetre C, Allen T, Habashy HO, Ellis IO, Rees R, Ball GR: DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. PLoS One 2014, 9(1):e84428.
30. Kozmik Z, Pfeffer P, Kralova J, Paces J, Paces V, Kalousova A, Cvekl A: Molecular cloning and expression of the human and mouse homologues of the Drosophila dachshund gene. Dev Genes Evol 1999, 209(9):537-545.
31. Yan W, Wu K, Herman JG, Brock MV, Fuks F, Yang L, Zhu H, Li Y, Yang Y, Guo M: Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics 2013, 8(12):1373-1383.
32. Wu L, Herman JG, Brock MV, Wu K, Mao G, Yan W, Nie Y, Liang H, Zhan Q, Li W, Guo M: Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-β signaling. Plos One 2014, 9(4):e95509.
33. Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X, Lisanti MP, Cvekl A, Birrer M, Pestell RG: Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell 2007, 18(3):755-767.
34. Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Müller-Tidow C, Golub TR, Kawakami K, Ford HL: The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proc Natl Acad Sci U S A 2004, 101(17):6478-6483.
35. Yu Y, Davicioni E, Triche TJ, Merlino G: The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res 2006, 66(4):1982-1989.
36. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3:5.
37. Roy S, Levi E, Majumdar AP, Sarkar FH: Expression of miR-34 is lost in colon cancer which can be re-expressed by a novel agent CDF. J Hematol Oncol 2012, 5:58.
38. Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, Zhang Q, Willmarth NE, Chepelev I, Crosariol M, Wei Z, Hu J, Zhao K, Pestell RG: Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem 2011, 286(3):2132-2142.
39. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER: Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 2002, 62(13):3803-3811.
40. Hedberg Y, Ljungberg B, Roos G, Landberg G: Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 2003, 88(9):1417-1423.
41. Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP: Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration. Int J Cancer 2012, 130(11):2693-2702.
42. Yuen JS, Sim MY, Siml HG, Chong TW, Lau WK, Cheng CW, Huynh H: Inhibition of angiogenic and non-Angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model. Br J Cancer 2011, 104(6):941-947.
43. Liu J, Li M, Song B, Jia C, Zhang L, Bai X, Hu W: Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol 2013, 31(2):264-270.
44. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ: Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol 2013, 6:65.
45. Hedberg Y, Davoodi E, Roos G, Ljungberg B, Landberg G: Cyclin-D1 expression in human renal-cell carcinoma. Int J Cancer 1999, 84(3):268-272.
46. Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, Hinds PW: Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010, 17(1):65-76.
47. Pestell RG, Li Z: Antisense to cyclin D1 inhibits VEGF-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 2006, 12(15):4459-4462.
48. Casimiro MC, Crosariol M, Loro E, Ertel A, Yu Z, Dampier W, Saria EA, Papanikolaou A, Stanek TJ, Li Z, Wang C, Fortina P, Addya S, Tozeren A, Knudsen ES, Arnold A, Pestell RG: ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J Clin Invest 2012, 122(3):833-843.
49. Saha MN, Qiu L, Chang H: Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 2013, 6:23.
50. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, Li A, Cveklova K, Kozmik Z, Lisanti MP, Russell RG, Cvekl A, Pestell RG: DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 2003, 278(51):51673-51684.
51. Chen DL, Zeng ZL, Yang J, Ren C, Wang DS, Wu WJ, Xu RH: L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol 2013, 6:43.
52. Shi K, Jiang Q, Li Z, Shan L, Li F, An J, Yang Y, Xu C: Sodium selenite alters microtubule assembly and induces apoptosis in vitro and in vivo. J Hematol Oncol 2013, 6:7.
53. Dong LH, Cheng S, Zheng Z, Wang L, Shen Y, Shen ZX, Chen SJ, Zhao WL: Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol 2013, 6:53.